(PharmaNewsWire.Com, July 05, 2017 ) The Europe Diabetic Retinopathy Market has been estimated at USD 1.10 billion in 2016 and is projected to reach USD 1.51 billion by 2021, at a CAGR of 6.55% during the forecast period from 2016 to 2021. The European diabetic retinopathy market holds the highest share in the market, driven by rising patient awareness levels, particularly in the Western European countries. Europe market is geographically segmented into Spain, Germany, Italy, UK and France.
Diabetic retinopathy is a medical condition which damages retina and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the disease at its initial stage.
Growth enhancing factors are government initiatives, abundant R&D activities, and skill set enhancement of healthcare providers. Such supportive initiatives coupled with rising awareness among patients are anticipated to result in lucrative growth. Treatment of diabetic retinopathy is expected to gain patients willingness for treatment by introducing advanced technology and reducing pain by using laser procedure with quick recovery time.
The Europe Diabetic Retinopathy Market has been segmented on the basis of indication into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is further sub segmented as Mild, Moderate and Severe. Based on Treatment type the market is bifurcated into Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy. By end users division is among Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. Augmented incidence of diabetes, lack of diagnosis at right time, and non-compliant retinal screening of diabetic patients are predicted to propel the growth of non-proliferative diabetic retinopathy market share.
The Major companies in Diabetic Retinopathy treatment market are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
